Chinese biopharma making biosimilar and innovative monoclonal antibodies for oncology and autoimmune disease.
Chinese biopharma making biosimilar and innovative monoclonal antibodies for oncology and autoimmune disease.
Earns from selling its own antibodies in China, from licensing overseas rights to partners that pay upfront and milestone fees and then buy supply, and from biosimilars, lower-cost versions of established cancer drugs. Fosun Pharma is the controlling shareholder.
In one line: A Chinese Amgen-biosimilars-style oncology antibody maker.
Moat: narrow (regulatory licence, scale, process know-how). Approved biosimilar manufacturing and regulatory track record across multiple markets.
Headquarters: Shanghai, China · Founded: 2010 · Employees: 3,762
Size Shanghai Henlius Biotech (2696.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $3.05B, the 329th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$43.46 on 18 Nov 2026.
Performance Over six months the shares fell 38.5%, against -1.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 32.6% over the last twelve months (peer median +14.8%); the operating margin is 12.0% (peer median 14.4%).
Valuation It trades at 21.3× forward earnings against a peer median of 21.5× (9th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +61%, so the hurdle is -47 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.7 points above its cost of capital (7.7% WACC).
Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$8.30B | HK$7.23B | HK$6.21B | HK$5.96B | HK$3.74B |
| Revenue growth | — | +16% | +4% | +59% | — |
| Gross profit | HK$6.13B | HK$5.36B | HK$4.48B | HK$4.26B | HK$2.65B |
| EBITDA | HK$1.47B | HK$1.35B | HK$1.35B | HK$1.09B | -HK$176M |
| Net income | HK$969M | HK$897M | HK$890M | HK$603M | -HK$809M |
| Free cash flow | HK$855M | HK$957M | HK$1.02B | HK$491M | HK$334M |
| Capital expenditure | HK$1.62B | HK$1.30B | HK$908M | HK$1.12B | HK$1.59B |
| Total debt | n/a | HK$4.01B | HK$3.88B | HK$4.51B | HK$4.14B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai Henlius Biotech 2696.HK | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% |
| Shanghai Junshi Biosciences 1877.HK | $3.49B | -38% | +36% | -14% | n/a | n/a |
| Amgen AMGN | $240B | +34% | +9% | 36% | 18.3× | 1.6% |
| Celltrion 068270.KS | $34.9B | +12% | +40% | 32% | 33.9× | 10.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2696.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.9% | -0.1% | 3rd lowest of 21 |
| 6-month return | -38.5% | -1.3% | 2nd lowest of 21 |
| Distance from 52-week high | -50.1% | -25.0% | 3rd lowest of 21 |
| Revenue growth (TTM) | +32.6% | +14.8% | 6th highest of 20 |
| Operating margin | 12.0% | 14.4% | 10th highest of 19 |
| Forward P/E | 21.3× | 21.5× | 9th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 14.1% | 1.1% | 5th most demanding of 14 |
| Growth delivered (Del g) | +61.4% | +7.0% | 2nd highest of 14 |
| Hurdle (Req g minus delivered) | -47.3 pp | -10.1 pp | 2nd least demanding of 14 |
| ROIC minus cost of capital | +1.7 pp | +4.3 pp | 8th lowest of 17 |
| EV / EBITDA | 18.7× | 27.6× | 4th cheapest of 8 |
| Net debt / EBITDA | 2.5× | -1.9× | 2nd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% | +61.4% |
| ACADIA Pharmaceuticals ACAD | United States | $3.08B | -15% | +15% | 10% | 17.8× | 9.2% | +19.4% |
| Vericel VCEL | United States | $2.99B | +66% | +25% | 8% | 68.3× | 46.5% | +17.3% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $2.99B | -1% | -11% | 24% | 20.1× | -3.3% | +7.0% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $3.12B | -42% | +50% | 3% | 34.2× | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.13B | -25% | +136% | 29% | 36.1× | 17.7% | +98.4% |
| China Medical System 0867.HK | Hong Kong | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% | +2.7% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.95B | +28% | +50% | 26% | 63.4× | n/a | n/a |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% | -9.6% |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.85B | 0% | -12% | 18% | 15.5× | -13.1% | +2.4% |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Betta Pharmaceuticals 300558.SZ | China | $2.70B | -15% | +16% | 11% | 38.0× | 23.2% | +14.0% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 44.7× | 37.4% | +6.1% |
| Shanghai Junshi Biosciences 688180.SS | China | $3.48B | -31% | +29% | -15% | n/a | n/a | n/a |